Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (581-590 of 704) with videos related to

Pageof 71
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapyAmelia M Taylor, Janet McKeown, Florentia Dimitriou, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2023
The features and management of acquired resistance to PD1-based therapy in metastatic melanomaAdriana Hepner, Judith M Versluis, Roslyn Wallace, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 16, 2024
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upT Amaral, M Ottaviano, A Arance, et al.
Pigment Cell & Melanoma Research|February 16, 2019
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodiesInes Pires da Silva, Isabella C Glitza, Lauren E Haydu, et al.
The Journal of Investigative Dermatology|November 23, 2021
Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous MelanomaUpekha E Liyanage, Stuart MacGregor, D Timothy Bishop, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteriaJames Larkin, Jeffrey Weber, Michele Del Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2024
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international studyMario Mandalà, Paul Lorigan, Maria Chiara Sergi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorDouglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.
Nature Communications|July 2, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 yearsClaus Garbe, Ulrike Keim, Teresa Amaral, et al.
Pageof 71

Showing results (581-590 of 704) with videos related to

Sort By:
Pageof 71
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapyAmelia M Taylor, Janet McKeown, Florentia Dimitriou, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2023
The features and management of acquired resistance to PD1-based therapy in metastatic melanomaAdriana Hepner, Judith M Versluis, Roslyn Wallace, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 16, 2024
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upT Amaral, M Ottaviano, A Arance, et al.
Pigment Cell & Melanoma Research|February 16, 2019
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodiesInes Pires da Silva, Isabella C Glitza, Lauren E Haydu, et al.
The Journal of Investigative Dermatology|November 23, 2021
Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous MelanomaUpekha E Liyanage, Stuart MacGregor, D Timothy Bishop, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteriaJames Larkin, Jeffrey Weber, Michele Del Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2024
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international studyMario Mandalà, Paul Lorigan, Maria Chiara Sergi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorDouglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.
Nature Communications|July 2, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 yearsClaus Garbe, Ulrike Keim, Teresa Amaral, et al.
Pageof 71